AI가 MA(Medical Affairs) 분야에서 더 스마트하고 신속한 의사 결정을 내리는 방법 : Expert Q&A

Transforming decision-making in medical affairs, AI offers numerous benefits and opportunities. Along with rapidly processing large data sets from clinical trials, real-world evidence (RWE) and scientific literature. It helps to identify and engage with key opinion leaders, optimising interactions and ensuring effective dissemination of information.

Generative AI tools like ChatGPT are improving the creation of written and visual content for communication with healthcare professionals (HCPs) and patients, enhancing both efficiency and quality. This allows medical affairs to focus on strategic tasks.

FirstWord spoke with Olivia Kager, medical lead for Kyowa Kirin's German, Austrian and Swiss territories, about how AI is impacting decision-making within the company's medical affairs functions.

Key Questions Answered:

• In what ways has AI started to impact decision-making processes in medical affairs at Kyowa Kirin?
• Can you share examples of areas where AI has improved outcomes or efficiencies?
• What are the biggest challenges in integrating AI-driven insights into strategic decision-making?
• How does AI enhance the analysis of clinical trial data and RWE in your role?
• How do you ensure the quality and accuracy of AI-generated content?
• Can you discuss any specific AI-driven projects that have led to better patient outcomes?
• What ethical considerations do you take into account when implementing AI in medical affairs?
• How do you address concerns about data privacy and security in AI applications?
• What future trends do you foresee in the use of AI in medical affairs?
• How is Kyowa Kirin and its medical affairs function preparing for the next wave of AI innovations in pharma?

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.